1
|
Le Guen C, Grain A, Le Calvez B, Saiagh S, Vrignaud F, Eveillard M, Clémenceau B, Zahar MB. [Can academic structures improve access to CAR-T cells?]. Bull Cancer 2024; 111:62-72. [PMID: 38030508 DOI: 10.1016/j.bulcan.2023.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 10/26/2023] [Accepted: 10/30/2023] [Indexed: 12/01/2023]
Abstract
In France, hospital cell therapy units have not been authorised to routinely produce chimeric antigen receptor T lymphocytes (CAR-T cells), which would then be referred to as academic CAR-T cells. CAR-T cells are classified as advanced therapy medicinal products and correspond to genetically modified T lymphocytes ex vivo. The CAR-T cell production process is complex and requires scientific and technical expertise to meet the acceptance criteria of the pharmaceutical quality system. The most commonly used method for genetically modifying T lymphocytes is viral transduction (lentiviral or retroviral), which requires prior access to a batch of good manufacturing practice (GMP) grade viral vector. Because of its cost, this reagent is the main limiting factor for developing CAR-T cells. A CAR-T cell produced by an industrial company is expensive (around €350,000 per injection) and the time taken by the manufacturer to make it available to the clinician can vary from three to five weeks. By meeting the economic and ecological challenges, can academic structures improve access to CAR-T cells? In this article, we present the elements necessary for the feasibility of setting up CAR-T cell production in an academic structure.
Collapse
Affiliation(s)
- Camille Le Guen
- Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France.
| | - Audrey Grain
- Unité d'oncologie pédiatrique, CHU de Nantes, 44093 Nantes, France; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, 44000 Nantes, France
| | | | - Soraya Saiagh
- Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France
| | - Florence Vrignaud
- Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France
| | - Marion Eveillard
- Unité d'hématologie biologique, CHU de Nantes, 44093 Nantes, France
| | - Béatrice Clémenceau
- Unité de thérapie cellulaire et génique, CHU de Nantes, 44093 Nantes, France; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, 44000 Nantes, France
| | | |
Collapse
|
2
|
Thariat J, Loiseau C. Basic concepts and directions in the radiation therapy quality assurance processes of clinical trials. Cancer Radiother 2023; 27:464-468. [PMID: 37541796 DOI: 10.1016/j.canrad.2023.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Accepted: 07/07/2023] [Indexed: 08/06/2023]
Abstract
The radiation therapy quality assurance of clinical trials is internationally recognized as a key factor to control the quality of radiotherapy for its impact on clinical trial's goals. Quality assessment may be performed at different levels and by different means, which are now quite standardized. The optimal radiation therapy quality assurance of clinical trials trade-off to maintain accrual rates, radiotherapy quality and optimize clinical trial research processes is yet to be defined. This article addresses current definitions, processes, limitations and directions.
Collapse
Affiliation(s)
- J Thariat
- Department of Radiation Therapy, centre François-Baclesse, 14000 Caen, France; Laboratoire de physique corpusculaire, IN2P3, EnsiCaen, CNRS UMR 6534, Normandie université, 14000 Caen, France.
| | - C Loiseau
- Department of Radiation Therapy, centre François-Baclesse, 14000 Caen, France
| |
Collapse
|
3
|
Khalladi N, Dejean C, Bosset M, Pointreau Y, Kinj R, Racadot S, Castelli J, Huguet F, Renard S, Guihard S, Tao Y, Rouvier JM, Johnson A, Bourhis J, Xu Shan S, Thariat J. A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients. Cancer Radiother 2021; 25:755-762. [PMID: 34565664 DOI: 10.1016/j.canrad.2021.04.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 04/19/2021] [Accepted: 04/28/2021] [Indexed: 11/25/2022]
Abstract
PURPOSE A Benchmark Case (BC) was performed as part of the quality assurance process of the randomized phase 2 GORTEC 2014-14 OMET study, testing the possibility of multisite stereotactic radiation therapy (SBRT) alone in oligometastatic head and neck squamous cell carcinoma (HNSCC) as an alternative to systemic treatment and SBRT. MATERIAL AND METHODS Compliance of the investigating centers with the prescription, delineation, planning and evaluation recommendations available in the research protocol was assessed. In addition, classical dosimetric analysis was supplemented by quantitative geometric analysis using conformation indices. RESULTS Twenty centers participated in the BC analysis. Among them, four major deviations (MaD) were reported in two centers. Two (10%) centers in MaD had omitted the satellite tumor nodule and secondarily validated after revision. Their respective DICE indexes were 0.37 and 0 and use of extracranial SBRT devices suboptimal There were significant residual heterogeneities between participating centers, including those with a similar SBRT equipment, with impact of plan quality using standard indicators and geometric indices. CONCLUSION A priori QA using a BC conditioning the participation of the clinical investigation centers showed deviations from good SBRT practice and led to the exclusion of one out of the twenty participating centers. The majority of centers have demonstrated rigorous compliance with the research protocol. The use of quality indexes adds a complementary approach to improve assessment of plan quality.
Collapse
Affiliation(s)
- N Khalladi
- Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France
| | - C Dejean
- Centre Antoine Lacassagne, Nice, France
| | - M Bosset
- Centre Marie Curie, Valence, France
| | | | - R Kinj
- Centre Antoine Lacassagne, Nice, France
| | | | | | - F Huguet
- Centre hospitalier et universitaire Tenon, Paris, France
| | - S Renard
- Institut de Cancérologie de Lorraine, Nancy, France
| | - S Guihard
- Institut de Cancérologie Strasbourg Europe, Strasbourg, France
| | - Y Tao
- Institut Gustave Roussy, Villejuif, France
| | - J M Rouvier
- Centre hospitalier régional et universitaire, Besançon-Montbéliard, France
| | - A Johnson
- Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France
| | - J Bourhis
- Centre hospitalier universitaire vaudois, Lausanne, Switzerland
| | - S Xu Shan
- Centre hospitalier universitaire vaudois, Lausanne, Switzerland
| | - J Thariat
- Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France; Corpuscular Physics Laboratory-Normandy University, Caen, France.
| |
Collapse
|
4
|
Thariat J, Calugaru V, Aloi D, Maingon P, Grégoire V. Head and neck proton therapy in France: A missed opportunity or a challenge in front of us? Cancer Radiother 2021; 25:537-544. [PMID: 34272183 DOI: 10.1016/j.canrad.2021.06.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 06/22/2021] [Accepted: 06/24/2021] [Indexed: 10/20/2022]
Abstract
Following major advances of the best of photon-techniques such as intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and, to arrive soon, magnetic resonance (MR)-linac radiotherapy, there are still substantial opportunities in the treatment of head and neck cancers to further reduce the toxicity burden. Proton therapy represents another attractive option in this high-quality and highly competitive precision radiotherapy landscape. Proton therapy holds promises to reduce toxicities and to escalate the dose in radioresistant cases or cases where dose distribution is not satisfactory with photons. However, the selection of patients for proton therapy needs to be done using evidence-based medicine to build arguments in favor of personalized precision radiation therapy. Referral to proton therapy versus IMRT or SBRT should be registered (ProtonShare® platform) and envisioned in a formalized clinical research perspective through randomized trials. The use of an enrichment process using a model-based approach should be done to only randomize patients doomed to benefit from proton. To tackle such great opportunities, the French proton therapy challenge is to collaborate at the national and international levels, and to demonstrate that the extra-costs of treatment are worth clinically and economically in the short, mid, and long-term. In parallel to the clinical developments, there are still preclinical issues to be tackled (e.g., proton FLASH, mini-beams, combination with immunotherapy), for which the French Radiotransnet network offers a unique platform. The current article provides a personal view of the challenges and opportunities with a focus on clinical research and randomized trial requirements as well as the needs for strong collaborations at the national and international levels for PT in squamous cell carcinomas of the head and neck to date.
Collapse
Affiliation(s)
- J Thariat
- Department of Radiation Oncology, Centre François-Baclesse, Caen, France; Laboratoire de physique Corpusculaire IN2P3/ENSICAEN/CNRS UMR 6534, Normandie Université, Caen, France; GORTEC - Intergroupe ORL, Tours, France.
| | - V Calugaru
- Department of Radiation Oncology, Institut Curie, Paris, France
| | - D Aloi
- Department of Radiation Oncology, Centre Antoine-Lacassagne, Côte d'Azur University, Provence-Alpes-Côte d'Azur, Nice, France
| | - P Maingon
- Department of Oncology Radiotherapy, CLIP (2) Galilée, Institut Universitaire de Cancérologie (IUC), Sorbonne University, Pitié Salpêtrière Hospital, AP-HP, Paris, France
| | - V Grégoire
- Radiation Oncology Department, Centre Léon-Bérard, Lyon, France
| |
Collapse
|
5
|
Gessen S, Daguenet E, Gras M, Louati S, Bouleftour W, Sotton S, Bosacki C, Magné N. How to improve clinical research in a department of radiation oncology. Bull Cancer 2020; 107:991-8. [PMID: 32950241 DOI: 10.1016/j.bulcan.2020.06.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Revised: 06/15/2020] [Accepted: 06/18/2020] [Indexed: 11/21/2022]
Abstract
INTRODUCTION Radiation therapy is a core modality for cancer treatment. Around 40% of cancer cures include the use of radiotherapy, either as a single strategy or combined with other treatments. In the past decade, substantial technical advances and novel insights into radiobiological properties have considerably improved patients' outcomes. This study overviewed the landscape of clinical research at our radiotherapy department. METHODS We surveyed our institutional database of clinical trials to collect information for completed or ongoing radiation therapy clinical trials, from 2005 to December 2017 at the Lucien Neuwirth cancer institute. RESULTS A total of 31 clinical trials were undertaken during the study period, of which 4 studies (12.9%) were industry-sponsored and 3 studies (9.7%) were launched by our radiotherapy unit. The vast majority of clinical trials (83.9%) were dedicated to unique organ localization, especially urological cancer (prostate or bladder) (42%). We also observed a shift towards more phase II trials during the study period as well as a special focus on elderly population. Over the last decade, the number of included patients increased by a 5.3 fold input, with 135 inclusions before 2011 and 720 inclusions after 2011. DISCUSSION This study provided an observational and comprehensive analysis of radiotherapy research. From a monocentric point-of-view, these results reflected the on-going progress of worldwide radiotherapy research. Based on a 13-years' experience, this study aimed at highlighting essential cues to ensure efficient and perennial research.
Collapse
|
6
|
Plaze M, Attali D, Petit AC, Blatzer M, Simon-Loriere E, Vinckier F, Cachia A, Chrétien F, Gaillard R. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. Encephale 2020; 46:169-172. [PMID: 32425222 PMCID: PMC7229964 DOI: 10.1016/j.encep.2020.05.006] [Citation(s) in RCA: 69] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Accepted: 05/11/2020] [Indexed: 12/29/2022]
Abstract
OBJECTIVES The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals. In Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff. This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties. Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis. Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity. METHODS In this context, the ReCoVery study aims to repurpose CPZ, a molecule with an excellent tolerance profile and a very high biodistribution in the saliva, lungs and brain. We hypothesize that CPZ could reduce the unfavorable course of COVID-19 infection among patients requiring respiratory support without the need for ICU care, and that it could also reduce the contagiousness of SARS-CoV-2. For this purpose, we plan a pilot, multicenter, randomized, single blind, controlled, phase III therapeutic trial (standard treatment vs. CPZ+standard treatment). CONCLUSION This repurposing of CPZ for its anti-SARS-CoV-2 activity could offer an alternative, rapid strategy to alleviate infection severity. This repurposing strategy also avoids numerous developmental and experimental steps, and could save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easily managed side effects.
Collapse
Affiliation(s)
- M Plaze
- GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Université de Paris, Paris, France.
| | - D Attali
- GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Université de Paris, Paris, France; Physics for Medicine Paris, Inserm, ESPCI Paris, CNRS, PSL Research University, Univ Paris Diderot, Sorbonne Paris Cite, Paris, France
| | - A-C Petit
- GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Institut Pasteur, Experimental Neuropathology Unit, Paris, France
| | - M Blatzer
- Institut Pasteur, Experimental Neuropathology Unit, Paris, France
| | - E Simon-Loriere
- Institut Pasteur, G5 Evolutionary Genomics of RNA Viruses, Paris, France
| | - F Vinckier
- GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Université de Paris, Paris, France
| | - A Cachia
- Université de Paris, Institut de Psychiatrie et Neurosciences de Paris, INSERM, Paris, France; Université de Paris, Laboratoire de Psychologie du développement et de l'Éducation de l'Enfant, CNRS, Paris, France
| | - F Chrétien
- Institut Pasteur, Experimental Neuropathology Unit, Paris, France; GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service de Neuropathologie, Paris, France
| | - R Gaillard
- GHU PARIS Psychiatrie & Neurosciences, site Sainte-Anne, Service Hospitalo-Universitaire, Pôle Hospitalo-Universitaire Paris 15, Paris, France; Université de Paris, Paris, France; Institut Pasteur, Experimental Neuropathology Unit, Paris, France
| |
Collapse
|
7
|
Plaze M, Attali D, Petit AC, Blatzer M, Simon-Loriere E, Vinckier F, Cachia A, Chrétien F, Gaillard R. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. Encephale 2020; 46:S35-S39. [PMID: 32387014 PMCID: PMC7188634 DOI: 10.1016/j.encep.2020.04.010] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 04/27/2020] [Indexed: 12/15/2022]
Abstract
OBJECTIVES The ongoing COVID-19 pandemic comprises a total of more than 2,350,000 cases and 160,000 deaths. The interest in anti-coronavirus drug development has been limited so far and effective methods to prevent or treat coronavirus infections in humans are still lacking. Urgent action is needed to fight this fatal coronavirus infection by reducing the number of infected people along with the infection contagiousness and severity. Since the beginning of the COVID-19 outbreak several weeks ago, we observe in GHU PARIS Psychiatrie & Neurosciences (Sainte-Anne hospital, Paris, France) a lower prevalence of symptomatic and severe forms of COVID-19 infections in psychiatric patients (∼4%) compared to health care professionals (∼14%). Similar observations have been noted in other psychiatric units in France and abroad. Our hypothesis is that psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments. Chlorpromazine (CPZ) is a phenothiazine derivative widely used in clinical routine in the treatment of acute and chronic psychoses. This first antipsychotic medication has been discovered in 1952 by Jean Delay and Pierre Deniker at Sainte-Anne hospital. In addition, to its antipsychotic effects, several in vitro studies have also demonstrated a CPZ antiviral activity via the inhibition of clathrin-mediated endocytosis. Recently, independent studies revealed that CPZ is an anti-MERS-CoV and an anti-SARS-CoV-1 drug. In comparison to other antiviral drugs, the main advantages of CPZ lie in its biodistribution: (i) preclinical and clinical studies have reported a high CPZ concentration in the lungs (20-200 times higher than in plasma), which is critical because of the respiratory tropism of SARS-CoV-2; (ii) CPZ is highly concentrated in saliva (30-100 times higher than in plasma) and could therefore reduce the contagiousness of COVID-19; (iii) CPZ can cross the blood-brain barrier and could therefore prevent the neurological forms of COVID-19. METHODS Our hypothesis is that CPZ could decrease the unfavorable evolution of COVID-19 infection in oxygen-requiring patients without the need for intensive care, but also reduce the contagiousness of SARS-CoV-2. At this end, we designed a pilot, phase III, multicenter, single blind, randomized controlled clinical trial. Efficacy of CPZ will be assessed according to clinical, biological and radiological criteria. The main objective is to demonstrate a shorter time to response (TTR) to treatment in the CPZ+standard-of-care (CPZ+SOC) group, compared to the SOC group. Response to treatment is defined by a reduction of at least one level of severity on the WHO-Ordinal Scale for Clinical Improvement (WHO-OSCI). The secondary objectives are to demonstrate in the CPZ+SOC group, compared to the SOC group: (A) superior clinical improvement; (B) a greater decrease in the biological markers of viral attack by SARS-CoV-2 (PCR, viral load); (C) a greater decrease in inflammatory markers (e.g. CRP and lymphopenia); (D) a greater decrease in parenchymal involvement (chest CT) on the seventh day post-randomization; (E) to define the optimal dosage of CPZ and its tolerance; (F) to evaluate the biological parameters of response to treatment, in particular the involvement of inflammatory cytokines. Patient recruitment along with the main and secondary objectives are in line with WHO 2020 COVID-19 guidelines. CONCLUSION This repositioning of CPZ as an anti-SARS-CoV-2 drug offers an alternative and rapid strategy to alleviate the virus propagation and the infection severity and lethality. This CPZ repositioning strategy also avoids numerous developmental and experimental steps and can save precious time to rapidly establish an anti-COVID-19 therapy with well-known, limited and easy to manage side effects. Indeed, CPZ is an FDA-approved drug with an excellent tolerance profile, prescribed for around 70 years in psychiatry but also in clinical routine in nausea and vomiting of pregnancy, in advanced cancer and also to treat headaches in various neurological conditions. The broad spectrum of CPZ treatment - including antipsychotic, anxiolytic, antiemetic, antiviral, immunomodulatory effects along with inhibition of clathrin-mediated endocytosis and modulation of blood-brain barrier - is in line with the historical French commercial name for CPZ, i.e. LARGACTIL, chosen as a reference to its "LARGe ACTion" properties. The discovery of those CPZ properties, as for many other molecules in psychiatry, is both the result of serendipity and careful clinical observations. Using this approach, the field of mental illness could provide innovative therapeutic approaches to fight SARS-CoV-2.
Collapse
Affiliation(s)
- M Plaze
- GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France; Université de Paris, Paris, France.
| | - D Attali
- GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France; Université de Paris, Paris, France; Physics for medicine Paris, Inserm, ESPCI Paris, CNRS, PSL Research university, université Paris Diderot, Sorbonne Paris Cite, Paris, France
| | - A-C Petit
- GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France; Institut Pasteur, experimental neuropathology unit, Paris, France
| | - M Blatzer
- Institut Pasteur, experimental neuropathology unit, Paris, France
| | - E Simon-Loriere
- Institut Pasteur, G5 evolutionary genomics of RNA viruses, Paris, France
| | - F Vinckier
- GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France; Université de Paris, Paris, France
| | - A Cachia
- Université de Paris, Institut de Psychiatrie et Neurosciences de Paris, INSERM, Paris, France; Université de Paris, Laboratoire de Psychologie du développement et de l'Éducation de l'Enfant, CNRS, Paris, France
| | - F Chrétien
- Institut Pasteur, experimental neuropathology unit, Paris, France; GHU PARIS Psychiatrie et Neurosciences, site Sainte-Anne, service de Neuropathologie, Paris, France
| | - R Gaillard
- GHU Paris psychiatrie et neurosciences, site Sainte-Anne, service hospitalo-universitaire, pôle hospitalo-universitaire Paris 15, Paris, France; Université de Paris, Paris, France; Institut Pasteur, experimental neuropathology unit, Paris, France
| |
Collapse
|
8
|
Rollando P, Parc C, Naudet F, Gaba JF. [Data sharing policies of clinical trials funders in France]. Therapie 2020; 75:527-536. [PMID: 32446662 DOI: 10.1016/j.therap.2020.04.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Revised: 01/09/2020] [Accepted: 04/03/2020] [Indexed: 11/16/2022]
Abstract
AIMS The aims of this survey were to evaluate the percentage of French clinical trial funders with a data sharing policy, to describe their data sharing policies and, more generally, the transparency of the research they fund. METHODS The different funders of clinical trials in France have been identified from 3 lists of tenders for clinical research projects: the internal list of the University Hospital Center (CHU) of Rennes, the list of the Interregional Group for Clinical Research and Innovation (GIRCI EST), the list of the portal for calls for projects in health research. Funders were contacted, first by email and then by phone (at least two email and/or phone reminders) to respond to an online survey via Google form. The questionnaire aimed to assess the existence of a sharing policy or not, as well as the way in which it was set up. RESULTS Out of 190 funders contacted, 94 did not respond. Sixty-five of the respondents were excluded because they did not fund clinical trials. Of the 31 funders included (including Direction générale de l'offre de soins [DGOS], Institut national contre le cancer [INCa], Groupement Interrégional de Recherche Clinique et d'Innovation [GIRCIs]), only 9 (29%) had implemented a data sharing policy. Among these nine funders, only one had a mandatory sharing policy and eight a policy supporting but not enforcing data sharing. Five allowed the use of budget lines dedicated to data sharing. Three reported granting data sharing incentives. Three had dedicated guidelines indicating a specific mode of sharing data (sharing on request and/or on a specialized platform) and specifying the type of data (individual patient data and/or protocol and amendments). For all three, there were restrictions on sharing data to researchers only. Data sharing policies concerned 19% of the total financial volume (850,032,000 euros) of the 26 funders who reported this information. CONCLUSION Despite international interest in clinical trial data sharing practices, clinical trials funders with a strong data-sharing policy remain an exception in France.
Collapse
Affiliation(s)
- Pauline Rollando
- Inserm, CIC 1414 (centre d'investigation clinique de Rennes), université Rennes, CHU Rennes, 35000 Rennes, France.
| | - Céline Parc
- Direction de la recherche et de l'innovation (DRI), CHU Rennes, 35000 Rennes, France
| | - Florian Naudet
- Inserm, CIC 1414 (centre d'investigation clinique de Rennes), université Rennes, CHU Rennes, 35000 Rennes, France
| | - Jeanne Fabiola Gaba
- Inserm, CIC 1414 (centre d'investigation clinique de Rennes), université Rennes, CHU Rennes, 35000 Rennes, France; REcherche en Pharmaco-Épidémiologie et REcours aux Soins (REPERES), 35000 Rennes, France
| |
Collapse
|
9
|
Vogin G, Wambersie A, Pötter R, Beuve M, Combs SE, Magrin G, Mayer R, Mock U, Sarrut D, Schreiner T, Fossati P, Balosso J. Concepts and terms for dose/volume parameters in carbon-ion radiotherapy: Conclusions of the ULICE taskforce. Cancer Radiother 2018; 22:802-809. [PMID: 30327228 DOI: 10.1016/j.canrad.2017.11.016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Revised: 11/24/2017] [Accepted: 11/29/2017] [Indexed: 01/24/2023]
Abstract
PURPOSE The Union of Light Ion Centers in Europe (ULICE) program addressed the need for uniting scientific results for carbon-ion radiation therapy obtained by several institutions worldwide in different fields of excellence, and translating them into a real benefit to the community. Particularly, the concepts for dose/volume parameters developed in photon radiotherapy cannot be extrapolated to high linear energy transfer particles. METHODS AND MATERIALS The ULICE-WP2 taskforce included radiation oncologists involved in carbon-ion radiation therapy and International Commission on Radiation Units and Measurements, radiation biologists, expert physicists in the fields of carbon-ion radiation therapy, microdosimetry, biological modeling and image-guided radiotherapy. Consensual reports emerged from multiple discussions within both the restricted group and the wider ULICE community. Public deliverables were produced and disseminated to the European Commission. RESULTS Here we highlight the disparity in practices between treating centers, then address the main topics to finally elaborate specific recommendations. Although it appears relatively simple to add geometrical margins around the clinical target volume to obtain the planning target volume as performed in photon radiotherapy, this procedure is not appropriate for carbon-ion radiation therapy. Due to the variation of the radiation quality in depth, there is no generic relative biological effectiveness value for carbon-ions outside of an isolated point, for a given fractionation and specific experimental conditions. Absorbed dose and "equieffective dose" for specified conditions must always be reported. CONCLUSIONS This work contributed to the development of standard operating procedures for carbon-ion radiation therapy clinical trials. These procedures are now being applied, particularly in the first phase III international, multicenter trial (PHRC Étoile).
Collapse
Affiliation(s)
- G Vogin
- Département de radiothérapie, institut de cancérologie de Lorraine Alexis-Vautrin, 54519 Vandœuvre-lès-Nancy cedex, France; CNRS, UMR 7365, ingénierie moléculaire et physiopathologie articulaire (Imopa), 54505 Vandœuvre-lès-Nancy cedex, France; Université de Lorraine, 54505 Vandoeuvre-lès-Nancy, France.
| | - A Wambersie
- Institut de recherche expérimentale et clinique (Irec), Molecular Imaging, Radiotherapy and Oncology (MIRO), cliniques universitaires Saint-Luc, 1200 Brussels, Belgium; Université catholique de Louvain (UCL), 1348 Louvain-la-Neuve, Belgium
| | - R Pötter
- Department of Radiotherapy, Comprehensive Cancer Center, Vienna, Austria; Medical University of Vienna, Vienna, Austria
| | - M Beuve
- Université Lyon 1, 69100 Villeurbanne, France; Institut de physique nucléaire de Lyon, 69622 Villeurbanne cedex, France
| | - S E Combs
- Klinik und Poliklinik für RadioOnkologie und Strahlentherapie, Technische Universität München (TUM), 81675 München, Germany; Instituts für Innovative Radiotherapie (iRT), Helmholtz Zentrum München, 85764 Oberschleißheim, Germany
| | - G Magrin
- EBG MedAustron GmbH, 2700 Wiener-Neustadt, Austria
| | - R Mayer
- EBG MedAustron GmbH, 2700 Wiener-Neustadt, Austria
| | - U Mock
- EBG MedAustron GmbH, 2700 Wiener-Neustadt, Austria
| | - D Sarrut
- Université Lyon 1, 69100 Villeurbanne, France; CNRS, UMR 5220 Laboratoire Creatis, 69100 Villeurbanne, France; Inserm, U1044 Laboratoire Creatis, 69100 Villeurbanne, France
| | - T Schreiner
- EBG MedAustron GmbH, 2700 Wiener-Neustadt, Austria
| | - P Fossati
- Università di Milano-Medicina e Chirurgia, Milano, Italy; Fondazione CNAO (Centro Nazionale di Adroterapia Oncologica), Pavia, Italy
| | - J Balosso
- Service de cancérologie-radiothérapie, hôpital Albert-Michallon, CHU Grenoble Alpes, 38043 Grenoble cedex 09, France; IPNL, France Hadron national research infrastructure, 69000 Lyon, France; Université Grenoble Alpes, 38400 Saint-Martin-d'Hères, France
| |
Collapse
|
10
|
Mondet F, Alimi JC, Boyer C. [Cancer plans apply to surgical treatment of prostate cancer: A geographically isolated center balance]. Prog Urol 2017; 27:337-344. [PMID: 28392433 DOI: 10.1016/j.purol.2017.03.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2016] [Revised: 01/25/2017] [Accepted: 03/07/2017] [Indexed: 12/01/2022]
Abstract
INTRODUCTION Since 2003, fight against cancer was structured by 3 national cancer programs (CP). The objective of this study is to evaluate the application of these measures in the case of surgical prostate cancer (PCa) treatment in a geographically isolated center. MATERIAL Monocentric retrospective study carried in a 100-bed clinic located 2hours away from a Cancer Regional Reference Center. Between August 2009 and December 2014, 251 consecutive patients were treated by total laparoscopic prostatectomy (TLP). Fifty-seven patients (22.7 %) received a secondary treatment after TLP. The study focused on the delay between prostate biopsies and PTL, the traceability of AD elements, the return of active patients, inclusion in clinical trials (GETUG 17, GETUG 20 and GETUG 22). Data were collected in September 2016. The follow-up defined by the time between the date of the last visit and the prostate biopsy allows a median follow-up of 43.1 months (2.4-80.5). RESULTS All elements of the CAP are totally gathered on 45 % of the patients (113/251). Thirty-four (13.5 %) patients were active at the time of the intervention. Thirty-one (91.2 %) will return to an identical activity after a median work stoppage of 1.7 month (0.25-6). Fourteen percent (35/251) of the patients are eligible to a clinical trial. Seventeen percent (6/35) of them were proposed to one of a trial after multidisciplinary meeting and 5.7 % (2/35) are eventually included in one trial. CONCLUSION CP define a course of high quality care. A better transparency of the founding of the enforceable measures and a better consideration for the local specificities should facilitate their application. The TLP treat the PCa with the reasonable objective of a return to an identical professional activity. The multidisciplinary meeting does not guarantee the participation to clinical trial, which depends mainly on distance from the Cancer Regional Reference Center and the vigilance of the Urologist. LEVEL OF EVIDENCE 4.
Collapse
Affiliation(s)
- F Mondet
- Cabinet d'urologie des Alpes du Sud, polyclinique des Alpes du Sud, 3-5, rue Antonin-Coronat, 05000 Gap, France.
| | - J-C Alimi
- Cabinet d'urologie des Alpes du Sud, polyclinique des Alpes du Sud, 3-5, rue Antonin-Coronat, 05000 Gap, France
| | - C Boyer
- Cabinet d'urologie des Alpes du Sud, polyclinique des Alpes du Sud, 3-5, rue Antonin-Coronat, 05000 Gap, France
| |
Collapse
|
11
|
Abstract
IMMUNOMODULATOR ANTIBODIES AND MELANOMA Recently, metastatic melanoma has known real therapeutic improvement. Since 2011, 8 drugs have been approved for advanced melanoma such as immunotherapy checkpoint inhibitors. Chemotherapy is no longer used in the first setting of metastatic melanoma treatment. In 2010, the advent of ipilimumab, an anti CTLA 4 inhibitor, changed the scenario and in the following years, many studies confirmed the efficacy of nivolumab and pembrolizumab, two anti PD 1 inhibitors, as a first line treatment. Furthermore, the combination of first-line nivolumab plus ipilimumab might lead to improved outcomes compared with first-line ipilimumab alone in patients with advanced melanoma. The results suggest encouraging survival outcomes with immunotherapy in this population of patients. However, the management of tumoral response and immune related toxicity, patient selection (what would be the most effective therapy for an individual patient?) are a real challenge.
Collapse
Affiliation(s)
- Cécile Pagès
- Service de dermatologie, Hôpital saint Louis, 1 av Claude Vellefaux 75010 Paris, 0142385312.
| | - Barouyr Baroudjian
- Service de dermatologie, Hôpital saint Louis, 1 av Claude Vellefaux 75010 Paris, 0142385312
| | - Celeste Lebbé
- Service de dermatologie, Hôpital saint Louis, 1 av Claude Vellefaux 75010 Paris, 0142385312
| |
Collapse
|
12
|
Nguyen-Xuan HT, Thiollier G, Ruault O, Fauconnier A, Lucot JP, Bader G. [Study of the factors motivating refusal of women to participate to a randomized clinical trial in gynecological surgery. Retrospective observational bicentric study]. ACTA ACUST UNITED AC 2016; 45:1054-1059. [PMID: 27114064 DOI: 10.1016/j.jgyn.2016.03.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2015] [Revised: 03/07/2016] [Accepted: 03/10/2016] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Randomized controlled trials (RCT) in surgery are often subject to difficulties inherent in the study design and recruitment of patients. Women's participation rate to RCTs in surgery is relatively low and varies from 30 to 70%. These recruitment problems might induce a weak scientific value and even stop the study. Thus, optimizing recruitment is a challenge for surgical research. In contemporary literature, we lack data on motivations and profile of women who refuse to participate in a RCT in surgery. OBJECTIVE To explore the potentially influential factors affecting women's decision to decline participation in PROSPERE trial, comparing laparoscopic sacrocolpopexy (LSCP) to vaginal mesh for cystocele repair. PATIENT AND METHOD Retrospective, observational, qualitative, bicentric study conducted in the department of gynecology of Poissy and Lille hospitals. Patients included were those who refused to participate to PROSPERE trial in both centers. Factors of non-participation in the trial were recorded at the time of the first visit. A control group consisted of women who agreed to participate in the trial was also analyzed. RESULTS In both centers, 139 were eligible to participate in the trial but 35 of them (25%) refused. Thirty-two women agreed to declare their refusal motivations. Vaginal mesh was finally performed in 18 (56,2%) patients and LSCP in 14 patients (43,8%). The control group consisted of 20 women, including 9 operated by vaginal mesh and 11 by LSCP. Patient's characteristics were similar in the both groups. Most influencing factor in refusal for participation was "previous choice of technique" in 50% cases (16/32), followed by "geographical remoteness and difficulties for additional visits" in 40.6% cases (13/32), and finally by "do not accept the concept of randomization" in 21.8% cases (7/32). The most influencing factor in women's acceptance was interest in helping others by "supporting medical research" in 100% cases (20/20), followed by "potential personal benefits and close follow-up" in 60% (12/20). CONCLUSION Our study identified the most influential factors relevant to women decision-making whether or not to participate in RCT in surgery. A number of factors leading to refusal of participation are potentially correctable leading to better recruitment rates in future RCTs. Optimization of information on the principle of randomization, limiting the number of additional visits could help researchers improve participation rates.
Collapse
Affiliation(s)
- H-T Nguyen-Xuan
- Département de gynécologie-obstétrique, CHI Poissy/Saint-Germain-en-Laye, 10, rue du Champ-Gaillard, 78300 Poissy, France.
| | - G Thiollier
- Département de gynécologie-obstétrique, CHI Poissy/Saint-Germain-en-Laye, 10, rue du Champ-Gaillard, 78300 Poissy, France
| | - O Ruault
- Département de gynécologie-obstétrique, CHRU de Lille, 2, avenue Oscar-Lambret, 59000 Lille, France
| | - A Fauconnier
- Département de gynécologie-obstétrique, CHI Poissy/Saint-Germain-en-Laye, 10, rue du Champ-Gaillard, 78300 Poissy, France
| | - J-P Lucot
- Département de gynécologie-obstétrique, CHRU de Lille, 2, avenue Oscar-Lambret, 59000 Lille, France
| | - G Bader
- Département de gynécologie-obstétrique, CHI Poissy/Saint-Germain-en-Laye, 10, rue du Champ-Gaillard, 78300 Poissy, France
| |
Collapse
|
13
|
Fournier C, Greillier L, Fina F, Secq V, Nanni-Metellus I, Loundou A, Garcia S, Ouafik L, Tomasini P, Barlesi F. [Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma]. Rev Mal Respir 2016; 33:751-756. [PMID: 27017063 DOI: 10.1016/j.rmr.2015.12.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Accepted: 12/01/2015] [Indexed: 11/15/2022]
Abstract
BACKGROUND EGFR tyrosine kinase inhibitors and crizotinib are nowadays the optimal treatment for metastatic lung cancer with activation of EGFR mutations and ALK rearrangement. In addition, several targeted agents are in development for lung cancer with other oncodrivers. In France, since 2011, six oncodrivers are routinely tested in patients with stage IV. The aim of this study was to assess whether systematic detection of oncodrivers and matched targeted therapy improve overall survival in patients with advanced lung adenocarcinoma. METHODS This study included all consecutive patients treated in our department for advanced lung adenocarcinoma from January 2012 to December 2013. We studied the impact in survival according to the presence of the driver and the targeted therapy. RESULTS Among the 261 patients included, oncodrivers alterations were found in 43.5% of patients: EML4-ALK fusion genes (2.1%), EGFR (10.3%), KRAS (27.7%), BRAF (2.5%), HER2 (0.8%), and PI3KCA (0.8%) mutations. Twenty-nine percent of patients (n=32) with oncodrivers received matched targeted therapy. Patient treated by targeted agent appropriate to an oncogenic driver had a median survival of 21.1 months (95% CI: 14.7-27.5). The patients (n=79) who did not receive targeted therapy had a median survival of 6.6 months (95% CI: 4.3-8.9). The patients (n=150) without identified driver had a median survival of 9.7 months (95% CI: 6.7-11.7); P<0.001. CONCLUSION An actionable oncodriver was routinely detected in nearly half of patients with advanced lung adenocarcinoma. This systematic detection may influence treatment outcomes, notably with matched targeted therapy.
Collapse
Affiliation(s)
- C Fournier
- Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13915 Marseille cedex 20, France.
| | - L Greillier
- Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13915 Marseille cedex 20, France; Faculté de médecine, Aix-Marseille université, Inserm U911 CRO2, 13915 Marseille, France
| | - F Fina
- Faculté de médecine, Aix-Marseille université, Inserm U911 CRO2, 13915 Marseille, France; Laboratoire de transfert d'oncologie biologique, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - V Secq
- Laboratoire d'anatomie pathologique, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - I Nanni-Metellus
- Faculté de médecine, Aix-Marseille université, Inserm U911 CRO2, 13915 Marseille, France; Laboratoire de transfert d'oncologie biologique, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - A Loundou
- Unité de recherche en santé publique, maladies chroniques et qualité de vie, EA 3279, Aix-Marseille université, 13915 Marseille, France
| | - S Garcia
- Laboratoire d'anatomie pathologique, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - L Ouafik
- Faculté de médecine, Aix-Marseille université, Inserm U911 CRO2, 13915 Marseille, France; Laboratoire de transfert d'oncologie biologique, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, 13915 Marseille, France
| | - P Tomasini
- Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13915 Marseille cedex 20, France; Faculté de médecine, Aix-Marseille université, Inserm U911 CRO2, 13915 Marseille, France
| | - F Barlesi
- Service d'oncologie multidisciplinaire et innovations thérapeutiques, Aix-Marseille université, Assistance publique-Hôpitaux de Marseille, chemin des Bourrely, 13915 Marseille cedex 20, France; Faculté de médecine, Aix-Marseille université, Inserm U911 CRO2, 13915 Marseille, France
| |
Collapse
|
14
|
Allouche G. [Sequential prescriptions: Arguments for a change of therapeutic patterns in treatment resistant depressions]. Encephale 2015; 42:32-8. [PMID: 26358484 DOI: 10.1016/j.encep.2015.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Accepted: 06/12/2014] [Indexed: 11/24/2022]
Abstract
Among the therapeutic strategies in treatment of resistant depression, the use of sequential prescriptions is discussed here. A number of observations, initially quite isolated and few controlled studies, some large-scale, have been reported, which showed a definite therapeutic effect of certain requirements in sequential treatment of depression. The Sequenced Treatment Alternatives to Relieve Depression Study (STAR*D) is up to now the largest clinical trial exploring treatment strategies in non psychotic resistant depression in real-life conditions with an algorithm of sequential decision. The main conclusions of this study are the following: after two unsuccessful attempts, the chance of remission decreases considerably. A 12-months follow-up showed that the higher the use of the processing steps were high, the more common the relapses were during this period. The pharmacological differences between psychotropic did not cause clinically significant difference. The positive effect of lithium in combination with antidepressants has been known since the work of De Montigny. Antidepressants allow readjustment of physiological sequence involving different monoaminergic systems together. Studies with tricyclic antidepressant-thyroid hormone T3: in depression, decreased norepinephrine at the synaptic receptors believed to cause hypersensitivity of these receptors. Thyroid hormones modulate the activity of adrenergic receptors. There would be a balance of activity between alpha and beta-adrenergic receptors, depending on the bioavailability of thyroid hormones. ECT may in some cases promote pharmacological response in case of previous resistance, or be effective in preventing relapse. Cognitive therapy and antidepressant medications likely have an effect on different types of depression. We can consider the interest of cognitive therapy in a sequential pattern after effective treatment with an antidepressant effect for treatment of residual symptoms, preventing relapses and recurrences, in antidepressant maintenance. These data support the interest of therapeutic strategies based on evolutionary criteria. Sequential models inspired by statistical methods may incorporate the effects of a future treatment by measuring the current one.
Collapse
Affiliation(s)
- G Allouche
- 24, boulevard de Strasbourg, 93600 Aulnay-sous-Bois, France.
| |
Collapse
|
15
|
Balez R, Leroyer C, Couturaud F. [Placebo effect: a contribution of social psychology]. Rev Mal Respir 2014; 31:714-20. [PMID: 25391506 DOI: 10.1016/j.rmr.2014.03.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2013] [Accepted: 01/12/2014] [Indexed: 11/21/2022]
Abstract
This article reviews the psychosocial variables, which are of interest in the relationship between the patient and the physician. According to a classical model of social psychology, such a relationship might contribute to the placebo/nocebo effects. We develop herein various relational and contextual variables, taking into account four dimensions (intra-individual, interpersonal, positional and ideological) and their potential effects on therapeutic responses. This applies both in the setting of daily clinical practice and of clinical trials. The placebo effect offers an opportunity for collaboration and dialogue between social scientists and physicians.
Collapse
|
16
|
Berbis J, Alessandrini M, Karsenty G, Auquier P. [Evaluating the efficacy of a new drug]. Prog Urol 2013; 23:1208-12. [PMID: 24183076 DOI: 10.1016/j.purol.2013.09.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2013] [Revised: 09/17/2013] [Accepted: 09/18/2013] [Indexed: 11/24/2022]
Abstract
AIM To give a practical guide for phase III clinical trial reading in order to evaluate independently the efficacy of a (new) drug therapy. METHOD Synthesis established by public health teachers and illustrated with examples in the field of urology. RESULTS A structured and simplified critical review of clinical trial remains the main way to "have an idea" of a new drug efficacy. Efficacy in clinical trial may be far from patient satisfaction, willingness to pursue with this treatment or cost-effectiveness relevance. CONCLUSION Knowledge of patient expectation, disease evolution and epidemiology have to be put side by side to raw efficacy data coming from phase III study in order to evaluate efficiency and effectiveness of new drugs therapy.
Collapse
Affiliation(s)
- J Berbis
- EA 3279 santé publique et maladies chroniques, faculté de médecine, Aix-Marseille université, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France
| | | | | | | |
Collapse
|
17
|
Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013; 169:737-43. [PMID: 24016464 DOI: 10.1016/j.neurol.2013.07.017] [Citation(s) in RCA: 94] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2013] [Accepted: 07/19/2013] [Indexed: 10/26/2022]
Abstract
The Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU) was formed to direct the design and management of interventional therapeutic trials of international DIAN and autosomal dominant Alzheimer's disease (ADAD) participants. The goal of the DIAN-TU is to implement safe trials that have the highest likelihood of success while advancing scientific understanding of these diseases and clinical effects of proposed therapies. The DIAN-TU has launched a trial design that leverages the existing infrastructure of the ongoing DIAN observational study, takes advantage of a variety of drug targets, incorporates the latest results of biomarker and cognitive data collected during the observational study, and implements biomarkers measuring Alzheimer's disease (AD) biological processes to improve the efficiency of trial design. The DIAN-TU trial design is unique due to the sophisticated design of multiple drugs, multiple pharmaceutical partners, academics servings as sponsor, geographic distribution of a rare population and intensive safety and biomarker assessments. The implementation of the operational aspects such as home health research delivery, safety magnetic resonance imagings (MRIs) at remote locations, monitoring clinical and cognitive measures, and regulatory management involving multiple pharmaceutical sponsors of the complex DIAN-TU trial are described.
Collapse
Affiliation(s)
- S M Mills
- DIAN-TU, Washington University, 660, S. Euclid Avenue, Campus Box 8111, St. Louis, MO 63108, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|